Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193024
Status:
TERMINATED
Last Update Posted:
2011-05-03
First Post:
2005-09-12
Brief Title:
Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
A Phase II Trial of EpirubicinDocetaxel in the First-Line Treatment of Patients With Metastatic Breast Cancer
Status:
TERMINATED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The epirubicindocetaxel combination is one of the most active and best tolerated taxaneanthracycline combinations In this phase II trial we will further evaluate the feasibility safety and effectiveness of the docetaxelepirubicin combination when administered as first-line treatment for metastatic breast cancer
Detailed Description:
Upon determination of eligibility all patients will receive
Docetaxel Epirubicin
Both drugs will be repeated at 21-day intervals
Docetaxel Epirubicin
Both drugs will be repeated at 21-day intervals
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GIA 11168 | None | None | None |
| 378-ONC-0030-219 | None | None | None |